Table of Contents
|
Analog Technologies, Inc. v. Analog Devices, Inc.
Contracts, Intellectual Property
US Court of Appeals for the First Circuit
|
Ithier v. Aponte Cruz
Contracts, Entertainment & Sports Law, Intellectual Property
US Court of Appeals for the First Circuit
|
INSULET CORP. v. EOFLOW, CO. LTD.
Business Law, Corporate Compliance, Drugs & Biotech, Health Law, Intellectual Property, Mergers & Acquisitions
US Court of Appeals for the Federal Circuit
|
Board of Regents of the University of Texas System v. IDEXX Laboratories, Inc.
Animal / Dog Law, Contracts, Intellectual Property
Supreme Court of Texas
|
Intellectual Property Opinions
|
Analog Technologies, Inc. v. Analog Devices, Inc.
|
Court: US Court of Appeals for the First Circuit
Docket:
23-1822
Opinion Date: June 18, 2024
Judge:
LYNCH
Areas of Law:
Contracts, Intellectual Property
|
The case involves Analog Technologies, Inc. ("ATI") and its CEO Dr. Gang Liu, who accused Analog Devices, Inc. ("ADI") of misappropriating trade secrets under federal and Massachusetts law. ATI claimed that they took reasonable measures to maintain the secrecy of development materials shared with ADI, and ADI violated its obligation to limit its use of those materials. The dispute originated from two agreements: a 2000 agreement, which included a confidentiality clause that expired five years after termination, and a 2015 agreement, which superseded the 2000 agreement and released ADI from any claims related to the 2000 agreement.
The U.S. District Court for the District of Massachusetts granted ADI's motion to dismiss the claim, ruling that any restrictions on ADI's use of the materials had expired under the clear terms of the written agreement among the parties. The court also found that there were no trade secrets under the 2000 agreement still in existence to have been misappropriated in 2021.
On appeal, the United States Court of Appeals for the First Circuit affirmed the lower court's decision. The appellate court concluded that ADI did not misappropriate the development materials as the restrictions on ADI's use of these materials under the 2000 agreement had expired in 2011. Furthermore, the 2015 agreement released ADI from any remaining use restrictions. The court also rejected the argument that ADI had a duty to limit its use of the materials at the time of the alleged misappropriation, as such a duty did not exist under the 2015 agreement.
|
|
Ithier v. Aponte Cruz
|
Court: US Court of Appeals for the First Circuit
Docket:
22-1859
Opinion Date: June 18, 2024
Judge:
Barron
Areas of Law:
Contracts, Entertainment & Sports Law, Intellectual Property
|
This case involves a dispute between the owners of El Gran Combo, one of the most popular Puerto Rican bands in history, and the band's former lead vocalist, Carlos Aponte-Cruz. The dispute centers on the interpretation of the Digital Performance Right in Sound Recordings Act of 1995, which entitles the "recording artist or artists featured on [a] sound recording" to a 45% share of certain royalties that the recording generated. Aponte-Cruz argues that he is the "artist . . . featured" on certain El Gran Combo sound recordings for which he was the lead vocalist and is therefore entitled to his portion of the 45% share of the statutory royalties for those recordings. The owners of El Gran Combo, on the other hand, contend that the band as an independent entity distinct from any of its individual members is the "artist . . . featured" on those recordings.
The United States District Court for the District of Puerto Rico ruled in favor of the owners of El Gran Combo, finding that the band, as a distinct legal entity, was the group most prominently featured on the sound recordings and thus entitled to collect the royalties as the featured artist. The court also ruled that Rafael Ithier, as the sole owner of El Gran Combo, was entitled to collect the featured artist royalties due to the corporation.
On appeal, the United States Court of Appeals for the First Circuit reversed the District Court's ruling. The appellate court concluded that even though the covers for the El Gran Combo albums that contain the disputed recordings refer only to the band itself and not to any of its individual members, Aponte-Cruz, as a "recording artist . . . featured" on the recordings in dispute, is entitled to his portion of the 45% share of the statutory royalties for those recordings. The court found that neither EGC Corp. nor Ithier is entitled to the 45% royalty share in the recordings at issue.
|
|
INSULET CORP. v. EOFLOW, CO. LTD.
|
Court: US Court of Appeals for the Federal Circuit
Docket:
24-1137
Opinion Date: June 17, 2024
Judge:
Lourie
Areas of Law:
Business Law, Corporate Compliance, Drugs & Biotech, Health Law, Intellectual Property, Mergers & Acquisitions
|
Insulet Corp. and EOFlow are medical device manufacturers that produce insulin pump patches. Insulet began developing its OmniPod product in the early 2000s, and EOFlow started developing its EOPatch product after its founding in 2011. Around the same time, four former Insulet employees joined EOFlow. In 2023, reports surfaced that Medtronic had started a process to acquire EOFlow. Soon after, Insulet sued EOFlow for violations of the Defend Trade Secrets Act (DTSA), seeking a temporary restraining order and a preliminary injunction to enjoin all technical communications between EOFlow and Medtronic in view of its trade secrets claims.
The U.S. District Court for the District of Massachusetts temporarily restrained EOFlow from disclosing products or manufacturing technical information related to the EOPatch or OmniPod products. The court then granted Insulet’s request for a preliminary injunction, finding strong evidence that Insulet is likely to succeed on the merits of its trade secrets claim, strong evidence of misappropriation, and that irreparable harm to Insulet crystallized when EOFlow announced an intended acquisition by Medtronic. The injunction enjoined EOFlow from manufacturing, marketing, or selling any product that was designed, developed, or manufactured, in whole or in part, using or relying on alleged trade secrets of Insulet.
The United States Court of Appeals for the Federal Circuit reversed the district court’s order. The court found that the district court had failed to address the statute of limitations, lacked a tailored analysis as to what specific information actually constituted a trade secret, and found it hard to tell what subset of that information was likely to have been misappropriated by EOFlow. The court also found that the district court had failed to meaningfully engage with the public interest prong. The court concluded that Insulet had not shown a likelihood of success on the merits and other factors for a preliminary injunction. The case was remanded for further proceedings consistent with the opinion.
|
|
Board of Regents of the University of Texas System v. IDEXX Laboratories, Inc.
|
Court: Supreme Court of Texas
Docket:
22-0844
Opinion Date: June 14, 2024
Judge:
HECHT
Areas of Law:
Animal / Dog Law, Contracts, Intellectual Property
|
The case revolves around a dispute between the Board of Regents of the University of Texas System and IDEXX Laboratories, Inc. over the interpretation of a patent licensing agreement. The agreement, signed in 2000, pertained to a peptide used to test for Lyme disease in dogs. The agreement stipulated different royalty rates for different types of products, depending on what tests were included. The dispute arose over the interpretation of two royalty provisions, one for 1% and the other for 2.5%, which could both be read to apply to the same sales of goods. IDEXX Laboratories had been paying the lower royalty rate, but the University argued that the higher rate should have been applied.
The trial court ruled in favor of the University, concluding that the licensing agreement was clear and unambiguous and that the University was entitled to recover the unpaid royalties claimed plus accrued interest. On appeal, IDEXX Laboratories argued for the first time that the licensing agreement was ambiguous. The court of appeals agreed, concluding that both interpretations of the royalty provisions were reasonable and conflicting, and therefore the agreement was ambiguous. It reversed the trial court's decision and remanded the case.
The Supreme Court of Texas disagreed with the court of appeals. It found that the royalty provisions were not ambiguous when read in the context of the licensing agreement itself and the objective circumstances in which the agreement was produced. The court concluded that the provisions were most reasonably interpreted to require royalties on IDEXX Laboratories' products at the higher rate stipulated in the agreement. The court reversed the court of appeals' judgment and remanded the case to that court for further proceedings.
|
|
|
About Justia Daily Opinion Summaries
|
Justia Daily Opinion Summaries is a free newsletter service with over 65 newsletters covering every federal appellate court and the highest court in each U.S. state.
|
Justia also provides weekly practice area newsletters in 60+ different practice areas. All daily and weekly Justia Newsletters are free. You may request newsletters or modify your preferences by visiting daily.justia.com.
|
Please note that some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on any summary for legal research purposes.
|
You may freely redistribute this email in whole.
|
About Justia
|
Justia’s mission is to make law and legal resources free for all.
|
More Free Upcoming Webinars |
|
|
Please visit individual webinar pages for more information about CLE
accreditation.
|
|